Answers are grounded in this paper and cite their sources.
Severe fever with thrombocytopenia syndrome (SFTS), characterized by an excessive inflammatory response and impaired adaptive immunity, is associated with a high risk of mortality. This study aims to establish and validate a machine learning (ML)-based predictive model integrating clinical and immune-inflammatory biomarkers for in-hospital mortality in patients with SFTS. A total of 238 patients, including 177 survivors and 61 non-survivors, were divided by stratified random sampling into a training cohort ( n = 167) and an internal validation cohort ( n = 71) at a 7:3 ratio. Features were selected from the intersection of Boruta, Least Absolute Shrinkage and Selection Operator (LASSO), and random forest recursive feature elimination (RF-RFE). Model hyperparameters were optimized exclusively within the training cohort using repeated stratified five-fold cross-validation, with the internal validation cohort reserved for final evaluation. Model performance was then assessed using the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis (DCA). SHAP (SHapley Additive exPlanations) was employed to improve model interpretability. To facilitate individualized risk estimation, the selected model was presented as a nomogram and incorporated into an interactive web-based calculator. The final logistic regression model incorporated four predictors: SFTSV RNA load, CD3+CD4+ T-cell count, IL-6, and PCT. In the internal validation cohort, the area under the ROC curve was 0.841 (95% CI: 0.736–0.930). Based on the maximum Youden index in the training cohort, the optimal cutoff probability was established at 0.2053. When this cutoff was applied to the validation cohort, the model yielded a sensitivity of 0.944 (95% CI: 0.742–0.990) and specificity of 0.698 (95% CI: 0.565–0.805). The model also demonstrated a Brier score of 0.139 (95% CI: 0.094–0.189) and potential net clinical benefit. We present an interpretable predictive model based on viral, immune, and inflammatory biomarkers for predicting in-hospital mortality in patients with SFTS. A multicenter prospective evaluation is highly recommended prior to its clinical use.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: